GSK partners with CEPI to develop vaccine for novel Coronavirus

This article was originally published here

Under the deal, GSK will provide its pandemic vaccine adjuvant technology to enhance the development of an effective vaccine against 2019-nCoV virus. Coronaviruses are a family of viruses

The post GSK partners with CEPI to develop vaccine for novel Coronavirus appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply